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PHASE II STUDY BLC2001: FIRST 
RESULTS OF ERDAFITINIB IN PATIENTS 
WITH METASTATIC OR UNRESECTABLE 
UROTHELIAL CARCINOMA AND FGFR 
ALTERATIONS
Erdafitinib is an FGFR inhibitor with activity in metastat-
ic urothelial carcinoma (mUC) harboring FGFR alterations. 
Due to low response to immune checkpoint inhibition (ICI) 
in this population, there is a need for new treatment options. 
At ASCO 2018, the first efficacy and safety results of a phase 
II study evaluating this agent were reported. A total of 99 pa-
tients with mUC (ECOG 0-2, progression during/following ≥ 
1 line of prior chemo or ≤ 12 months of [neo]adjuvant chemo, 
or cisplatin ineligible, prespecified FGFR alterations) were 
administered erdafitinib 8 mg daily continuous in 28-day 
cycles with possible up-titration to 9 mg daily. A median of 5 
cycles was administered. There was a 40% confirmed objec-
tive response rate (ORR) (3% complete response [CR], 37.4% 
partial response [PR]) and the disease control rate (DCR) 
was reported at 82%. Most patients (76%) showed some kind 
of tumor reduction with a median duration of response of 
5.6 months with 21% of patients who remain on treatment. 
Among patients who received prior ICI (N=21), the ORR was 
59. The median progression-free (PFS) and overall survival 
(OS) were 5.5 months and 13.8 months; respectively. Adverse 
events (AEs) were manageable with only 7% of patients dis-
continuing treatment due to a treatment-related AE (TRAE; 
grade 3/4 stomatitis, diarrhea and hyperphosphatemia). 
In conclusion, therapy with erdafitinib yielded a robust ORR 
and was tolerable in patients with mUC and FGFR alterations, 
especially in those who received prior ICI. FDA approval has 
been given based on this phase II trial. Further evaluation in 
the phase III THOR trial is currently ongoing.1
SAFETY AND EFFICACY OF 
NEOADJUVANT IMMUNOTHERAPY IN 
MUSCLE INVASIVE UC: FIRST INTERIM 
RESULTS OF THE ABACUS AND PURE-01 
PHASE II STUDIES
Atezolizumab and pembrolizumab are two ICIs used for 
treatment of mUC. Safety and efficacy results of neoadjuvant 
atezolizumab (ABACUS) or pembrolizumab (PURE-01) giv-
en prior to cystectomy in operable muscle invasive UC were 
presented at ASCO 2018.
In the ABACUS trial, 74 patients received two cycles of 
atezolizumab 1200mg q3w prior to cystectomy in muscle 
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invasive UC (T2/3/4N0M0; 73%, 20% and 7%, respectively). 
Imaging was performed at baseline and prior to cystectomy 
(4-8 weeks after start atezolizumab) to assess radiological re-
sponse. The median age was 73 years (range 54-88). Fifteen 
patients (20%) had only 1 cycle of atezolizumab of which 
8 due to AEs. Seven patients did not undergo cystectomy. 
Treatment was manageable with only 9% grade 3/4 TRAEs 
and one treatment-related death due to dyspnea. The patho-
logical CR (pCR) rate was 29% (20/68) with higher rates 
for PD-L1-postive patients (40%) versus PD-L1-negative pa-
tients (16%). Down-staging to non-muscle invasive disease 
was seen in 39% of patients. In total, 47 patients had sequen-
tial imaging and measurable disease at baseline. Of those, 
28% and 17% showed radiological response and progression. 
Notably, the PD-L1 positivity and the CD8 count increased 
from pre- to post-treatment. However, the impact of these 
biomarkers on the treatment outcome is yet to be elucidated.2
In the PURE-01 study, a total of 43 patients (predominant-
ly UC histology and cT≤3bN0 stage [63% cT3 versus 37% 
cT2], regardless of cisplatin eligibility) received 3 cycles of 
pembrolizumab 200mg q3w before radical cystectomy. Dis-
ease assessment as well as biomarker analysis (IHC Dako 
22C3 PD-L1 combined positive score [CPS] and genomic 
sequencing for tumor mutational burden [TMB]) was per-
formed. Sixty-one percent of patients had a tumor mutation 
burden (TMB) > 10 mutations/megabase (mut/Mb) and 9% 
had a TMB > 20 mut/Mb. All tumors were microsatellite sta-
ble. Pembrolizumab was found to be safe with only one pa-
tient suffering from a grade 3 ALT increase and 6 patients 
reporting reversible grade 2 AEs. At the time of the interim 
analysis, 25 patients were evaluable. A pCR was observed in 
40% of patients with 51% of patients showing down-stag-
ing to non-muscle invasive disease. In TURB samples, the 
mean CPS score for patients with a pCR was 30% as com-
pared to 10% for non-pCR patients (p=0.0549). Median TMB 
was comparable in both groups. Further genomic analysis 
showed that PBRM1 and RB1 mutations are clearly associ-
ated with pCR.3
Based on the findings of both trials, atezolizumab and pem-
brolizumab are safe and clearly show efficacy in this patient 
cohort urging the need for further follow-up. Biomarker re-
search shows promise for response prediction, but further 
validation is warranted.2,3
KEYNOTE-427: PEMBROLIZUMAB AS 
MONOTHERAPY FOR ADVANCE CLEAR 
CELL RENAL CELL CARCINOMA?
ICI combination therapy shows clinical benefit in the first-
line advanced clear cell renal cell carcinoma (ccRCC). How-
ever, data are scarce on the clinical impact of PD-1 inhibitor 
monotherapy as a first-line treatment option. In the phase 
II Keynote-427 trial, the efficacy and safety of pembroli-
zumab is being assessed in both advanced ccRCC and non-
ccRCC. At ASCO 2018, results from the ccRCC cohort were 
presented. A total of 110 patients (histologically confirmed 
ccRCC, no prior systemic therapy, measurable disease and 
Karnofsky performance status ≥70%) were administered 
pembrolizumab 200 mg q3w for 2 years or until confirmed 
progressive disease, unacceptable toxicity, or patient with-
drawal. In this efficacy analysis, with a median follow-up 
of 12.1 months, 108 patients with a median age of 64 years 
(range 29-87) were included. Patients were predominantly 
male (78%) and were classified as IMDC risk category favor-
able (37%), intermediate (47%), and poor (16%). The con-
firmed ORR was 38% (3 CR and 39 PR), 59% showed DCR 
for more than 6 months and 67% of patients showed a re-
duction in tumor burden (Figure 1). Median duration of re-
sponse was not reached. ORR for patients with favorable or 
intermediate/poor risk IMDC was 32% and 42%, respective-
ly. Otherwise, patients with CPS ≥ 1 showed an ORR of 50% 
whereas this was only half in patients with CPS < 1 (26%). 
Median PFS and OS were 8.7 months and not reached; re-
spectively.  TRAEs occurred in 80% of patients with most 
commonly reported AEs being pruritus (27%), fatigue (25%), 
diarrhea (19%), rash (16%), arthralgia (13%), and hypothy-
roidism (10%). Grade 3-5 TRAEs were noticed in 22% of cas-
es. Monotherapy with pembrolizumab for first-line treatment 
of advanced ccRCC demonstrated promising efficacy and ac-
ceptable tolerability, especially in PD-L1+ tumors. 4
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FIGURE 1. Efficacy of pembrolizumab as first-line mono-
therapy in advanced renal cell carcinoma A total of 74 patients 
experienced tumor shrinkage of whom 16 experienced 
a ≥80% reduction and 8 a 100% reduction.4
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TO OPERATE OR NOT TO OPERATE: 
ROLE OF CYTOREDUCTIVE 
NEPHRECTOMY IN METASTATIC RCC
Cytoreductive nephrectomy has been the standard-of-care in 
mRCC for the past twenty years. However, the efficacy of tar-
geted therapies is challenging this standard. The randomized, 
non-inferiority, phase III CARMENA trial was designed to 
answer the question whether upfront cytoreductive nephrec-
tomy should continue to be performed before TKI adminis-
tration. Over a period of 8 years (!), 450 patients with mRCC 
(ccRCC histology, PS 0-1, absence of symptomatic brain me-
tastasis, acceptable organ function and eligible for sunitinib) 
were randomized (1:1) to either cytoreductive nephrectomy 
followed by sunitinib 50 mg daily q4/6w (arm A) or suni-
tinib alone (arm B). The median age of patients in the trial 
was 62 years and the intermediate/poor MSKCC risk group 
distribution was 56%/44% in arm A and in 59%/41% in arm 
B. Median follow-up was 50.9 months at time of analysis. No 
difference between arm A and arm B was observed in terms 
of ORR (27% vs. 29%), PFS (7.2 vs. 8.3 months; HR[95%-
CI]: 0.82[0.67-1.00]), or OS (13.9 vs. 18.4 months; HR[95%-
CI]: 0.89[0.71-1.10]), independent of the MSKCC risk group 
(Figure 2). 
Based on these findings, the authors conclude that sunitinib 
alone is not inferior to cytoreductive nephrectomy followed 
by sunitinib and that cytoreductive nephrectomy should no 
longer be offered as standard-of-care when medical treat-
ment is required. However, this trial population may not be 
the ideal group to test this hypothesis as the median size of 
the primary tumor was 89 mm, with a median burden of 
metastatic disease of 14cm. Furthermore, patients with 
large primary tumors with only limited metastatic burden 
were not included. Next, due to the rise of immunothera-
py in earlier lines of treatment, the need for TKIs remains 
unclear. On the other hand, offering sunitinib instead of 
cytoreductive nephrectomy could lead to the formation of 
more neoantigens for immunotherapy priming with pri-
mary tumor still in place and the inflammation response 
after surgery could promote tumor growth. It is therefore 
not clear which option should be presented to the patient 
at the current time. In diffuse metastatic disease, start of 
systemic treatment with TKI does not seem inferior to ne-
phrectomy followed by TKI.5,6 
POST-OPERATIVE SORAFENIB IN 
PATIENTS WITH RCC WHO UNDERWENT 
RADICAL METASTASECTOMY: EFFICACY 
RESULTS FROM THE PHASE II RESORT 
TRIAL
Radical metastasectomy followed by observation is a com-
monly used strategy for some patients with mRCC. In the 
RESORT trial, the clinical benefit of angiogenesis inhibition 
after radical metastasectomy is prospectively assessed in 132 
patients.7 At the interim analysis, 68 mRCC patients (pre-
vious nephrectomy, predominant ccRCC histology, radical 
excision of no more than 3 metastases) were randomized 
(1:1) within 12 weeks from surgery to receive sorafenib 400 
mg twice daily (N=32) or observation (N=36) for a maxi-
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FIGURE 2. Survival outcome of cytoreductive nephrectomy – sunitinib (blue) vs. sunitinib alone (red). A. Similar OS was 
noticed for patients who did not undergo cytoreductive nephrectomy. B. Radiographic PFS was comparable between both 
groups. One-, two-, and three-year OS rates are indicated by the vertical dashed lines. The horizontal dashed line indicates 
the median. Tick marks indicate censored data.5,6
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mum of 52 weeks. Patients were stratified according to time 
from nephrectomy to metastases, site of disease and for the 
number of lesions. Radiologic restaging was performed ev-
ery 12 weeks. After a median follow-up of 21 months, the 
median recurrence-free survival (RFS) was 29 months in the 
sorafenib arm as compared to 35 months in the observation 
arm. One-year and 2-year RFS was 62% and 52% in patients 
treated with sorafenib whereas this was 74% and 59% for pa-
tients who were only observed following metastasectomy. No 
differences in RFS were observed considering the stratifica-
tion factors. Grade 3 AEs were 22% vs. 3% for sorafenib vs. ob-
servation and only 2 patients received the full sorafenib dose 
during the course of the trial. Sorafenib did not affect RFS 
in patients with mRCC after complete metastasectomy and 
resulted in increased toxicities pointing out that TKIs have 
no place as adjuvant therapy and watchful waiting remains 
a valid treatment option in these patients.8
SURVIVAL BENEFIT OF ABIRATERONE 
ACETATE PLUS A LHRH AGONIST ON 
BIOCHEMICAL RECURRENCE IN 
HORMONE-SENSITIVE NON-METASTATIC 
PROSTATE CANCER
Intermittent vs. continuous androgen deprivation (ADT) is 
an acceptable treatment for hormone-sensitive non-metastat-
ic prostate cancer (mPCa) leading to an improved quality of 
life with no significant survival difference. As abiraterone ac-
etate improves survival in hormone-sensitive mPCa, the sur-
vival benefit of the combination of abiraterone acetate and 
intermittent ADT was evaluated in a non-metastatic setting. 
Of 200 patients enrolled, 197 patients (hormone-sensitive 
non-mPCa, no definitive local treatment possible) were ran-
domized (1:1) to 8 months of abiraterone acetate (1 g daily) + 
prednisone (5 mg daily) + leuprolide (LHRH agonist) vs. leu-
prolide only. Cross-over was allowed upon progression. Strat-
ification factors were radical prostatectomy vs. radiation, PSA 
≥ vs. < 10 µg/L and time to recurrence ≥ vs. <  3 years. The me-
dian age of patients in the study was 65 years (range 42-85), 
the median PSA 1 was µg/L (0.3-33.3) and the median testos-
terone level was reported to be 346 ng/dL (160-946). Th vast 
majority of patients (94%) had undergone radical prostatec-
tomy. A total of 128 patients had PSA relapse. The PSA PFS 
was significantly higher in patients receiving the combina-
tion for 8 months vs. patients receiving only the LHRH ago-
nist (28.3 vs. 21.1 months; HR[95%CI]: 0.62[0.44-0.88]) with 
no difference in time to testosterone recovery. The combina-
tion of therapies also proved to be favorable across all strati-
fication factors. The most common grade 3 AEs reported in 
the combination arm were hypertension (5 patients) and liv-
er function disorders (4 patients). 
In summary, 8 months treatment with abiraterone acetate 
plus a LHRH agonist in hormone-sensitive non-mPCa im-
proves PSA PFS without a delay in testosterone recovery or 
significant safety concerns.9
NOVEL THERAPEUTIC OPTIONS FOR 
POST-DOCETAXEL METASTATIC 
CASTRATION-RESISTANT PROSTATE 
CANCER
The inhibitor olaparib was previously shown to be asso-
ciated with an improved ORR in patients with metastatic 
castration-resistant PCa (mCRPC) with a homologous re-
combination repair mutation.10 In the currently presented 
phase II trial, the combination of abiraterone acetate plus 
olaparib in post-chemotherapy patients with mCRPC was 
assessed independent of the presence of homologous re-
combination repair mutations. In total, 142 patients were 
randomized post-docetaxel (1:1) to receive olaparib (300 
mg twice daily) or placebo plus abiraterone acetate (1 g 
daily) until disease progression. The ORR was similar be-
tween olaparib and placebo (27% vs. 32%), while the radio-
graphic PFS was significantly higher in the olaparib arm 
as compared to the comparator arm (13.8 vs. 8.2 months; 
HR[95%CI]: 0.65[0.44-0.97]). This radiographic PFS ben-
efit was seen irrespective of the homologous recombina-
tion repair mutation status (wild type [N=35]: 15.0 vs. 9.7 
months / mutated [N=21]: 17.8 vs. 6.5 months / unknown 
[N=86]: 13.1 vs. 6.4 months). The median OS was 22.7 
months vs. 20.9 months (HR[95%CI]: 0.91[0.60-1.38]). In 
the olaparib arm, more grade ≥3 (54% vs. 28%), serious 
AEs (34% vs. 18%) and treatment discontinuation (30% 
vs. 10%) was reported. The time to quality-of-life deterio-
ration was similar in both arms (5.7 vs. 6.0 months). This 
is the first trial to show a radiographic survival benefit for 
mCRPC patients treated with a PARP inhibitor combined 
with abiraterone acetate. Safety data were however less fa-
vorable, and no overall survival (OS) benefit was noticed. 
Although a phase III trial is planned, this combination 
should not be offered as second-line therapy to patients 
who progressed on docetaxel.11
Secondly, preliminary results have shown antitumor ac-
tivity of ICI in PD-L1-positive patients with mCRPC (Key-
note-028).12 The phase II Keynote-199 trial evaluates 
the efficacy and safety of pembrolizumab monotherapy 
in docetaxel-refractory mCRPC. At ASCO 2018, results 
from the first 3 cohorts was presented. Patients (ECOG 
PS 0-2, ≥1 novel endocrine therapy [e.g. abiraterone, en-
zalutamide], 1-2 prior chemotherapies including docetaxel) 
were enrolled into three cohorts: RECIST-measurable 
PD-L1-positive disease (C1; N=131), RECIST-measurable 
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PD-L1-negative disease (C2; N=67), and non-measurable, 
bone-predominant disease (C3; N=60). All patients re-
ceived pembrolizumab 200 mg q3w until disease progres-
sion or intolerable toxicity. The ORR was evaluated every 
9 weeks during the first year and every 12 weeks thereaf-
ter. The median follow-up for for C1, C2 and C3 was 8.1, 
7.9 and 11.8 months, respectively. Antitumor activity was 
observed in all cohorts (Table 1). The ORR was numerically 
higher in patients with somatic BRCA1/2 or ATM mutations 
(11%). Median OS was 9.5 months, 8.0 months, and not 
reached for C1, C2 and C3; respectively. Grade ≥3 TRAEs 
were similar between cohorts with 14% of grade ≥3 AEs 
reported in total. Two treatment-related deaths occurred 
(pneumonitis and sepsis). These data show that pembroli-
zumab has antitumor activity and disease control with ac-
ceptable safety in post-docetaxel patients with mCRPC. 
Further evaluation and comparison to standard-of-care in 
large phase III trials is warranted.13
CLINICAL OUTCOME OF 3 DIFFERENT 
RADIUM-223 DOSE REGIMENS IN 
CHEMOTHERAPY-NAÏVE BONE mCRPC
The standard dose of Radium-223 55 kBq/kg q4w for 6 
cycles improved OS and delayed onset of skeletal-related 
events (SREs) in patients with only bone mCRPC.14 The 
current study investigated different Radium-223 treat-
ment regimens in a similar patient population. A total of 
391 patients were randomized (1:1:1) to Radium-223 stan-
dard dose (SD), Radium-223 high dose 88 kBq/kg q4w for 
up to 6 cycles (HD), or to Radium-223 standard dose ex-
tended q4w for up to 12 cycles (EXT). Treatment comple-
tion occurred in 65%, 52% and 22% of patients in the SD, 
HD and EXT arms, respectively. No significant SRE-free 
survival differences were observed between SD and HD 
(12.3 vs. 12.9 months; HR[95%CI]: 1.06[0.88-1.27]) and 
between SD and EXT (13.2 vs. 10.8 months; HR[95%CI]: 
1.26[0.94-1.69]). Median PFS and OS were 6.3 and 15.8 
months, 7.5 and 16.0 months, and 6.1 and 14.4 months 
in the SD, HD and EXT arms, respectively. The most fre-
quent TRAEs were fatigue, anemia and nausea. Grade ≥3 
TRAEs were reported in 34%, 48% and 53% of patients in 
the SD, HD and EXT arms; with anemia (13%), bone pain 
(5%), thrombocytopenia (4%) and hypertension (4%) being 
the most frequent. As the standard dose of Radium-223 is 
non-inferior to a higher or extent dose with more favorable 
safety profile, the currently approved dose and schedule of 
Radium-223 should be maintained as standard therapy.15
DOES RACE AFFECT OS IN MEN WITH 
mCRPC?
Previous reports of relatively small studies have suggested 
that African-American men with mCRPC have a shorter OS 
than Caucasian men. The primary goal of the present study 
was therefore to compare the OS in African-American men 
to the survival of Caucasian men treated with docetaxel/
prednisone or a docetaxel/prednisone containing regimen. 
Patient data from 8,871 men with mCRPC randomized in 
nine phase III trials were collected and prognostic impor-
tance of race on OS was evaluated, adjusting for established 
risk factors that were common across the trials (age, PSA, 
performance status, alkaline phosphatase, hemoglobin, and 
sites of metastases). In total, 8,452 patients were eligible, 
namely 7,528 (85%) Caucasian and 500 (6%) African-Amer-
ican men. The median age was 69 years and 94% of patients 
had a performance status 0-1. The median OS was 21.0 
months for African-American as compared to 21.2 months 
in Caucasian men, respectively. A multivariable analysis ad-
justing for established risk factors proved favorable for Af-
rican-American versus Caucasian men (HR[95%CI]: 0.81 
[0.72-0.92]). As such, these results are in controversy with 
previously reported data. Therefore, further understanding 
of the biological variation by race in men with mCRPC treat-
ed with any form of docetaxel/prednisone containing regi-
men is needed.16
TABLE 1. Response rates of pembrolizumab in docetaxel-refractory mCRPC.13
RECIST v1.1 C1 C2 C3 C1 + C2 C1 + C2 + C3
ORR, % 5 (2-11) 3 (<1-10) NA 5 (2-8) NA
DCR, % 22 (15-30) 24 (14-36) 37 (25-50) 23 (17-29) 26 (21-32)
DoR, months 8.4 (1.6-NR) NR (4.4-NR) NA 8.4 (1.9-NR) NA
DCR ≥ 6 months, % 9 (5-16) 6 (2-15) 22 (12-34) 8 (5-13) 11 (8-16)
mCRPC: metastatic castration-resistant prostate cancer; DCR: disease control rate; DoR: duration of response; NA: not 
applicable; N: not reached; ORR: objective response rate.
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KEY MESSAGES FOR CLINICAL PRACTICE
1   Erdafitinib for treatment of mUC with FGFR alterations yields robust ORR, especially when received prior ICI 
(FDA approval - phase III trial ongoing).
2   Atezolizumab and pembrolizumab are safe and show efficacy as neoadjuvant therapy in muscle invasive UC 
with down-staging to non-muscle invasive disease – further follow-up needed.
3   Pembrolizumab as first-line monotherapy for advanced ccRCC demonstrated promising efficacy and accepta-
ble tolerability, especially in PD-L1-postive tumors and could become a next treatment  in first-line RCC.
4   Sunitinib alone is not inferior to cytoreductive nephrectomy followed by sunitinib for mRCC. However, due 
to trial shortcomings, cytoreductive nephrectomy followed by TKI administration should remain the stan-
dard-of-care in most of our patients.
5   Sorafenib results in increased toxicity without affecting RFS in patients with mRCC after complete metasta-
sectomy. As such, TKIs have no place as adjuvant therapy and a watchful waiting should be offered.
6   Abiraterone acetate plus LHRH agonist in hormone-sensitive non-mPCa improves PSA PFS without a delay in 
testosterone recovery or significant safety concerns.
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